<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00622258</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001C1104</org_study_id>
    <nct_id>NCT00622258</nct_id>
  </id_info>
  <brief_title>A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study assesses the tolerability, safety, efficacy and pharmacokinetics of everolimus in&#xD;
      Japanese patients. Everolimus is administered orally everyday to adult patients with relapsed&#xD;
      or refractory non-Hodgkin's lymphoma who have progressed despite standard therapy or for whom&#xD;
      standard systemic therapy dose not exist.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety and tolerability of RAD001 in Japanese patients with relapsed or refractory non-Hodgkin's lymphoma</measure>
    <time_frame>whole study period</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the pharmacokinetics in Japanese patients</measure>
    <time_frame>1st sycle</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To seek preliminary evidence of efficacy in this population</measure>
    <time_frame>Every 2 cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolmus</intervention_name>
    <arm_group_label>Everolimus</arm_group_label>
    <other_name>RAD001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patients must have histopathologically confirmed diagnosis of non-Hodgkin's lymphoma&#xD;
&#xD;
          -  Patients must have disease that is either relapsed or refractory after at least one&#xD;
             prior treatment regimen and must not be eligible for any standard treatments&#xD;
&#xD;
          -  Patients must not have received autologous stem cell transplant at least within 12&#xD;
             weeks prior to study treatment. If patients received autologous stem cell transplant&#xD;
             more than 12 weeks ago, they must be fully recovered from the side effects of such&#xD;
             treatment&#xD;
&#xD;
          -  Patients who have not received autologous stem cell transplant must be either&#xD;
             ineligible for the treatment or, if eligible, patients must have chosen not to receive&#xD;
             stem cell transplant&#xD;
&#xD;
          -  Patients must have at least one measurable lesion&#xD;
&#xD;
          -  Age above 20 years old&#xD;
&#xD;
          -  Performance Status 0, 1, or 2 on Eastern Cooperative Oncology Group (ECOG) scale&#xD;
&#xD;
          -  Patients with a life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Patients must be willing to provide portion of bone marrow aspirate and biopsy during&#xD;
             study&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patients with history of another primary malignancy that is currently clinically&#xD;
             significant or currently requires active intervention&#xD;
&#xD;
          -  Patients with prior allogeneic stem cell transplant&#xD;
&#xD;
          -  Patients who have not recovered from the side effects of any major surgery (defined as&#xD;
             requiring general anesthesia) or patients that may require major surgery during the&#xD;
             course of the study&#xD;
&#xD;
          -  Patients who have received radiation therapy for ≤ 28 days prior to first study&#xD;
             treatment or who have not recovered from side effects of such therapy.&#xD;
&#xD;
          -  Patients who have received any other investigational agents ≤28 days prior to the&#xD;
             first study treatment&#xD;
&#xD;
          -  Patients who have received anti-neoplastic therapy within 28 days (60 days for&#xD;
             monoclonal antibody or radioimmunotherapy) prior to the first study treatment or who&#xD;
             have not recovered from side effects of such therapy&#xD;
&#xD;
          -  Patients who have received treatment with oral or intravenous steroids or any&#xD;
             immunosuppressive agents ≤ 28 days prior to the first study treatment&#xD;
&#xD;
          -  Patients who have received prior therapy with RAD001 or other mTOR inhibitors&#xD;
&#xD;
          -  Patient with prior therapy of &gt; 450 U blomycin&#xD;
&#xD;
          -  Patients with an active, bleeding diathesis.&#xD;
&#xD;
          -  Treatment with any hematopoietic colony-stimulating growth factors (e.g., G-CSF) ≤ 14&#xD;
             days prior to the first study treatment&#xD;
&#xD;
          -  Patients who have an impairment of gastrointestinal function or who have&#xD;
             gastrointestinal disease that may significantly alter the absorption of study&#xD;
             treatment (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea,&#xD;
             malabsorption syndrome)&#xD;
&#xD;
          -  Patients with active respiratory (excluding interstitial lung disease), skin, mucosal,&#xD;
             renal, neurological, or ocular disorder of grade &gt; 1&#xD;
&#xD;
          -  Patients with a history of interstitial lung disease of grade ≥ 1&#xD;
&#xD;
          -  Patients with a known history of human immunodeficiency virus seropositivity,&#xD;
             hepatitis B or C seropositivity&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya-city</city>
        <state>Aichi</state>
        <zip>466-8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Isehara-city</city>
        <state>Kanagawa</state>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sendai-city</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyoto</city>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.afinitor.com</url>
    <description>Visit NovartisClinicalTrials.com: Pre-qualify for a trial, and view a list of trials and participating study centers.</description>
  </link>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=13003</url>
    <description>Results for CRAD001C1104 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>February 12, 2008</study_first_submitted>
  <study_first_submitted_qc>February 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2008</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>everolimus</keyword>
  <keyword>mTOR inhibitor</keyword>
  <keyword>non-Hodgkin's lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

